Results 11 to 20 of about 28,814 (216)
Topical Imiquimod for Oral Cavity Leukoplakia and Dysplasia: A Scoping Review. [PDF]
Otolaryngol Head Neck SurgAbstract Objective Imiquimod, a toll‐like receptor 7 agonist, is currently FDA‐approved for treatment of actinic keratoses, superficial BCC, and external genital warts. It has also demonstrated promise in off‐label use in the treatment of oral cavity leukoplakia and dysplasia.
Scharner MK +3 more
europepmc +2 more sources
Case of large lentigo maligna melanoma of the scalp treated with 5% and 3.75% Imiquimod,
Anais Brasileiros de Dermatologia, 2021 The paper presents a case of lentigo maligna melanoma of the scalp in an elderly patient treated for the nodular part with surgery and the residual melanoma in situ with 5% Imiquimod and subsequently with 3.75% Imiquimod (each concentration for 4 months,
Miriam Rovesti +3 more
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2020 Treatment for toxoplasmosis is not completely successful because of their unwanted side effects, and new treatments are needed. Imiquimod has ability to moderate immune response and used to treat a wide variety of infections and tumors.
Leila Zaki +4 more
doaj +1 more source
Roles of TLR7 in activation of NF-κB signaling of keratinocytes by imiquimod. [PDF]
PLoS ONE, 2013 Imiquimod is known to exert its effects through Toll-like receptor 7 (TLR7) and/or TLR8, resulting in expression of proinflammatory cytokines and chemokines.
Zheng Jun Li +12 more
doaj +1 more source
Circadian control of interferon-sensitive gene expression in murine skin. [PDF]
, 2020 The circadian clock coordinates a variety of immune responses with signals from the external environment to promote survival. We investigated the potential reciprocal relationship between the circadian clock and skin inflammation.
Andersen, Bogi +9 more
core +2 more sources
Journal for ImmunoTherapy of Cancer, 2022 Background The complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod.
Natasja Hendriks +12 more
doaj +1 more source
pharma-kritik, 2004 Imiquimod ist ein lokal anwendbarer Immunmodulator, der bisher zur Behandlung von Warzen im anogenitalen Bereich zugelassen ist. Die Substanz besitzt zudem ein therapeutisches Potential bei Basaliomen und aktinischen Hautschäden sowie möglicherweise bei anderen Hautkrankheiten.
openaire +2 more sources
Journal of Dermatological Treatment, 2001 In this ever-expanding world of immunologic advancements, Drs Langley and Pearson have undertaken this timely, succinct review of imiquimod. Given its direct actions on monocytes and macrophages, as well as the many diverse cytokine effects that follow from these events, topical imiquimod has already solidly established itself as a successful treatment
G W, Pearson, R G, Langley
openaire +2 more sources
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy [PDF]
, 2017 BACKGROUND. Actinic keratosis is a precursor to cutaneous squamous cell carcinoma. Long treatment durations and severe side effects have limited the efficacy of current actinic keratosis treatments.
Ahu Turkoz +18 more
core +2 more sources
TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain [PDF]
, 2016 Background: The relationship between the brain and the immune system has become increasingly topical as, although it is immune-specialised, the CNS is not free from the influences of the immune system.
A Boivin +53 more
core +2 more sources